| Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone ER Sharlow, KV Giridhar, CR LaValle, J Chen, S Leimgruber, R Barrett, ... Journal of Biological Chemistry 283 (48), 33516-33526, 2008 | 154 | 2008 |
| Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century S Yadav, D Karam, I Bin Riaz, H Xie, U Durani, N Duma, KV Giridhar, ... Cancer 126 (1), 26-36, 2020 | 137 | 2020 |
| Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility CR LaValle, K Bravo-Altamirano, KV Giridhar, J Chen, E Sharlow, ... BMC chemical biology 10, 1-16, 2010 | 99 | 2010 |
| A contemporary review of male breast cancer: current evidence and unanswered questions RA Leon-Ferre, KV Giridhar, TJ Hieken, RW Mutter, FJ Couch, ... Cancer and Metastasis Reviews 37, 599-614, 2018 | 83 | 2018 |
| Hereditary cancer syndromes—A primer on diagnosis and management: Part 1: Breast-ovarian cancer syndromes NJ Samadder, KV Giridhar, N Baffy, D Riegert-Johnson, FJ Couch Mayo Clinic Proceedings 94 (6), 1084-1098, 2019 | 73 | 2019 |
| Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer M Du, KV Giridhar, Y Tian, MR Tschannen, J Zhu, CC Huang, D Kilari, ... Oncotarget 8 (38), 63703, 2017 | 59 | 2017 |
| Hereditary cancer syndromes—a primer on diagnosis and management, part 2: gastrointestinal cancer syndromes NJ Samadder, N Baffy, KV Giridhar, FJ Couch, D Riegert-Johnson Mayo Clinic Proceedings 94 (6), 1099-1116, 2019 | 50 | 2019 |
| A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-κB activities J Chen, KV Giridhar, L Zhang, S Xu, QJ Wang Carcinogenesis 32 (8), 1198-1206, 2011 | 42 | 2011 |
| Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer KV Giridhar, M Kohli Mayo Clinic Proceedings 92 (10), 1564-1582, 2017 | 36 | 2017 |
| Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors KV Giridhar, T Shanafelt, PK Tosh, SA Parikh, TG Call Leukemia & lymphoma 58 (8), 1973-1976, 2017 | 32 | 2017 |
| Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial TC Haddad, VJ Suman, AB D’Assoro, JM Carter, KV Giridhar, ... JAMA oncology 9 (6), 815-824, 2023 | 27 | 2023 |
| Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer KV Giridhar, C Sanhueza, DW Hillman, H Alkhateeb, R Carlson, W Tan, ... Prostate cancer and prostatic diseases 21 (3), 431-437, 2018 | 23 | 2018 |
| Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer D Yee, C Isaacs, DM Wolf, C Yau, P Haluska, KV Giridhar, ... NPJ Breast Cancer 7 (1), 131, 2021 | 18 | 2021 |
| Whole blood mRNA expression-based prognosis of metastatic renal cell carcinoma KV Giridhar, CP Sosa, DW Hillman, C Sanhueza, CL Dalpiaz, BA Costello, ... International journal of molecular sciences 18 (11), 2326, 2017 | 18 | 2017 |
| Available and emerging molecular markers in the clinical management of breast cancer KV Giridhar, MC Liu Expert Review of Molecular Diagnostics 19 (10), 919-928, 2019 | 17 | 2019 |
| Topical cannabinoids for treating chemotherapy-induced neuropathy: a case series S D’Andre, S McAllister, J Nagi, KV Giridhar, E Ruiz-Macias, C Loprinzi Integrative cancer therapies 20, 15347354211061739, 2021 | 12 | 2021 |
| Abstract P6-18-09: Clinical management of metastatic breast cancer (MBC) after CDK 4/6 inhibitors: A retrospective single-institution study KV Giridhar, GM Choong, RA Leon-Ferre, CC O'Sullivan, KJ Ruddy, ... Cancer Research 79 (4_Supplement), P6-18-09-P6-18-09, 2019 | 10 | 2019 |
| Clinical management of metastatic breast cancer after CDK4/6 inhibitors: a retrospective single-institution study KV Giridhar, GM Choong, RA Leon-Ferre, CC O'Sullivan, KJ Ruddy, ... San Antonio Breast Cancer Symposium, 2018 | 8 | 2018 |
| Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan … L Huppert, R Mahtani, S Fisch, N Dempsey, S Premji, A Raimonde-Taylor, ... Cancer Research 84 (9_Supplement), PS08-04-PS08-04, 2024 | 6 | 2024 |
| Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences? S Yadav, KV Giridhar, J Taraba, R Leon-Ferre, KJ Ruddy Expert Opinion on Drug Safety 19 (8), 923-926, 2020 | 6 | 2020 |
